Harmony Biosciences reported a strong third quarter in 2025, achieving $239.5 million in net revenue—a 29% year-over-year increase—while raising its revenue guidance for the year.

• Record patient additions for WAKIX, averaging 8,100 patients, a significant increase of 500 patients this quarter.
• Q3 net revenue guidance raised from $820 million to a new range of $845 million to $865 million, driven by strong commercial performance.
• Robust cash generation of $106 million, increasing total cash reserves to $778 million.
• Harmony is poised for future growth with ongoing development of its late-stage pipeline, including multiple upcoming catalyst events.